EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020

Hamed Khalili, Anders Forss iD, Jonas Söderling, Gabriella Bröms, Carl Eriksson iD, Jiangwei Sun iD, Jonas F Ludvigsson, Ola Olén

Inflammatory Bowel Diseases · 01.10.2025 · 31 (10) · 2787-2797

DOI: 10.1093/ibd/izaf077 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 25.04.2025. Verfasst von Hamed Khalili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translation Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bengt Ihre Research Fellowship, Swedish Research Council, Karolinska Institutet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Statins reduce the risk of inflammatory bowel disease (IBD), however their effect on IBD disease progression is largely unknown.

Methods

We linked Swedish healthcare registers and performed a nationwide cohort study (2006-2020) of 19 788 adults (≥18 years) with ulcerative colitis (UC) and 12 582 with Crohn’s disease (CD). Of these, 1733 with UC and 962 with CD were identified as incident statin users after UC or CD diagnosis. After 1:1 propensity score matching, we compared statin users with non-users to estimate the risk of IBD-related surgery, hospitalizations, and disease flares expressed as incidence rates (IRs) and multivariable-adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). For outcomes with statistically significant estimates, we calculated the numbers needed to treat (NNT).

Results

During a median follow-up of 3.4 years we observed a reduced risk of IBD-related surgery in statin users (UC, IR: 3.4 [95%CI: 2.1-4.8] per 1000 person-years; CD, IR: 9.2 [6.2-12.2]) compared with non-users in UC (IR: 6.3 [4.2-8.5]; aHR: 0.55 [0.31-0.97]) and CD (IR: 15.4 [11.0-19.7]; aHR: 0.54 [0.33-0.88]). The NNT to avoid one IBD-related surgical event per year of statin treatment were 345 (UC) and 161 (CD). For statin users, the risks of hospitalizations (IR: 17.0 [13.9-20.2]; aHR: 0.68 [0.51-0.91]) and disease flares (IR: 207.4 [193.2-221.6]; aHR: 0.86 [0.77-0.97]) were reduced in UC, but not in CD (IR: 20.3 [15.8-24.9]; aHR: 0.78 [0.56-1.09] and IR: 245.5 [223.9-267.1]; aHR: 1.02 [0.88-1.19]). In UC, NNT for hospitalizations and disease flares were 145 and 15.

Conclusions

Statins were associated with a reduced risk of IBD-related surgery, hospitalizations, and disease flares in patients with UC, and with a reduced risk of IBD-related surgery in patients with CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCrohn DiseaseColitis, UlcerativeInflammatory Bowel DiseasesHumansFemaleMaleAdultSwedenMiddle AgedDisease ProgressionHospitalizationRegistriesCohort StudiesIncidenceFollow-Up StudiesSeverity of Illness IndexAgedYoung AdultPropensity Score

Stichwörter der Autor:innen

Crohn’s diseaseinflammatory bowel diseasestatinssurgeryulcerative colitis

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Clinical and Translation Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Division of Gastroenterology, Department of Specialist Medicine, Danderyd Hospital, Stockholm, Sweden.
  • Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

ORCID-Profile: Anders Forss, Carl Eriksson, Jiangwei Sun

Förderung

  • Bengt Ihre Research Fellowship
  • Swedish Research Council
  • Karolinska Institutet

Zitieren

APA

Khalili, H., Forss, A., Söderling, J., Bröms, G., Eriksson, C., Sun, J., Ludvigsson, J. F., & Olén, O. (2025). Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020. Inflammatory Bowel Diseases, 31(10), 2787-2797. https://doi.org/10.1093/ibd/izaf077

Vancouver

Khalili H, Forss A, Söderling J, Bröms G, Eriksson C, Sun J, et al. Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020. Inflammatory Bowel Diseases. 2025;31(10):2787-2797. doi:10.1093/ibd/izaf077

BibTeX
@article{Khalili2025,
  author = {Khalili, Hamed and Forss, Anders and Söderling, Jonas and Bröms, Gabriella and Eriksson, Carl and Sun, Jiangwei and Ludvigsson, Jonas F and Olén, Ola},
  title = {Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {10},
  pages = {2787--2797},
  doi = {10.1093/ibd/izaf077}
}
Kostenlos starten →